Table 3.
Parameter estimates of latent growth models for anti-RBD and sVNT
| Covariates | Bivariate models |
Multivariate model |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Initial antibody levels |
Evolution of antibody levels |
Initial antibody levels |
Evolution of antibody levels |
|||||||||
| Estimate | 95%CI | p | Estimate | 95%CI | p | Estimate | 95%CI | p | Estimate | 95%CI | p | |
| Anti-RBD | ||||||||||||
| Sex (ref. female) | 0.114 | –0.044; 0.272 | 0.157 | –0.028 | –0.049; –0.007 | 0.008 | 0.116 | –0.041; 0.273 | 0.147 | –0.028 | –0.049; –0.007 | 0.010 |
| Age | <0.001 | –0.006; 0.007 | 0.984 | <0.001 | –0.001; 0.001 | 0.955 | –0.003 | –0.010; 0.004 | 0.381 | <0.001 | –0.001; 0.001 | 0.668 |
| Any comorbidity | 0.106 | –0.049; 0.262 | 0.181 | 0.008 | –0.016; 0.026 | 0.631 | 0.012 | –0.148; 0.172 | 0.882 | 0.016 | –0.005; 0.038 | 0.134 |
| Viral load | 0.020 | –0.026; 0.065 | 0.395 | 0.008 | –0.001; 0.011 | 0.139 | 0.006 | –0.039; 0.050 | 0.804 | 0.005 | –0.001; 0.011 | 0.105 |
| Symptom density score |
0.284 |
0.113; 0.454 |
0.001 |
<0.001 |
–0.023; 0.024 |
0.979 |
0.310 |
0.129; 0.490 |
0.001 |
–0.013 |
–0.037; 0.011 |
0.292 |
| sVNT | ||||||||||||
| Sex (ref. female) | 0.096 | –0.042; 0.235 | 0.173 | 0.104 | –0.036; 0.244 | 0.144 | ||||||
| Age | 0.005 | –0.001; 0.011 | 0.083 | 0.002 | –0.004; 0.008 | 0.443 | ||||||
| Any comorbidity | 0.170 | 0.035; 0.306 | 0.014 | 0.110 | –0.032; 0.252 | 0.130 | ||||||
| Viral load | 0.021 | –0.020; 0.062 | 0.320 | 0.007 | –0.033; 0.047 | 0.734 | ||||||
| Symptom density score | 0.252 | 0.102; 0.402 | 0.001 | 0.239 | 0.078; 0.399 | 0.004 | ||||||
RBD, receptor binding domain of spike protein; sVNT, surrogate virus neutralization assay; CI, confidence interval.